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Rationing
How much will Herceptin really cost?
Ann Barrett, Tom Roques, Matthew Small, Richard D Smith
New guidance from the National Institute for Health and Clinical Excellence recommends
Herceptin in early breast cancer, but it provides no additional funding or any suggestion of which
services to cut. This leaves medical staff with difficult decisions to make
In the United Kingdom the “value for money” of new
medical technologies is formally assessed through the
National Institute for Health and Clinical Excellence
(NICE), which commissions cost effectiveness analyses.
These analyses are summarised in terms of cost per
quality adjusted life year. Services with a cost per qual-
ity adjusted life year less than £30 000 are usually
viewed as good value for money, and NICE will recom-
mend their adoption by the National Health Service.1 2
The debate over trastuzumab (Herceptin) in early
breast cancer has highlighted a major deficiency in the
system—although NICE now recommends adopting
this new technology, it provides no extra funding and
does not suggest what cuts should be made to release
these extra funds.3 We outline how the cost of giving
Herceptin should not be measured in money alone,
but also in the treatments that will have to be dropped
to balance the books.
The Herceptin debate
Herceptin is a monoclonal antibody against the HER2
protein that is overexpressed in 20-25% of patients
with breast cancer. For palliation and in certain other
clinical circumstances, NICE recommended its use in
women whose tumours have high (3+) expression of
the HER2 receptor.4 The NICE appraisal of Herceptin
as adjuvant treatment has just been released, and the
National Cancer Research Institute has also issued
clinical guidelines.3 5
Readers will be aware of the heated debate
surrounding this treatment.6 7 The media have made
little mention of the restricted categories of patients for
whom Herceptin may be appropriate, or of the lack of
long term toxicity data, especially concerning effects
on the heart. Although the three published trials
showed a statistically significant improvement in rates
of recurrence, as yet, only one has shown a benefit in
survival (4.8% at four years).8–10 Despite the lack of
NICE approval at the time, several patients obtained
Herceptin through their local NHS by appealing to the
courts.11 NICE promised to “fast track” Herceptin, and
it is no surprise that the resulting guidance is positive.12
This means that our trust (Norfolk and Norwich
University Hospital) will have to find £1.9m (€2.9m;
$3.6m) each year in drug costs alone to make Hercep-
tin available to the 75 patients who may be eligible.
This becomes £2.3m if the costs of pathology testing,
cardiac monitoring, pharmacy preparation, and drug
administration are added. On the face of it, the answer
to our question is simple—Herceptin will cost our trust
£2.3m—but the real cost lies in the services that will be
cut to provide this money. This is an important element
currently missing from the debate.
Cost effectiveness comparison
To illustrate this, we audited drug costs in the oncology
centre of our hospital. We then hypothesised how we
could save £1.9m by cutting curative and palliative
chemotherapy treatments (tables 11 and 2).
The sum of £1.9m would enable us to treat 75
patients with Herceptin, but at four times the cost of
the adjuvant treatments shown in table 1. These treat-
ments have been proved to be clinically effective and
their estimated cost effectiveness is far greater than
that currently expected for Herceptin. The cost of giv-
ing adjuvant Herceptin is double that of all the pallia-
tive treatments shown in table 2.
So we could fund Herceptin if we did not treat 355
patients receiving adjuvant treatment (16 of whom
would be cured) or 208 patients receiving palliative
chemotherapy, and if we found £0.5m from another
source. These untreated patients will be people we
know. We will be the ones to tell them they are not get-
ting a treatment that has been proved to be effective,
which costs relatively little, because it is not the
“treatment of the moment.”
These results are obviously not definitive, but illus-
trate the fundamental challenge facing the NHS—the
tension between national priority setting and local
implementation.13 Currently central government allo-
cates the overall NHS budget to primary care trusts
and other substructures. Local bodies, such as primary
care trusts, then divide these funds between primary
and secondary care, treatment, and prevention, etc.14
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The situation is more complex for long term
treatments (such as Herceptin), which—under practice
based commissioning—fall on primary care budgets
rather than hospitals. Although in practice this means
that Herceptin may eventually be vying with other
clinical areas, such as paediatrics or orthopaedic
surgery, it does not affect the central message of our
example here—that the real cost of Herceptin is in the
other patients not treated, whether they are patients
with cancer or those with other conditions. NICE gives
no guidance on this issue. The current situation with
Herceptin highlights our central argument—that as
NICE guidance provides no extra funding or
suggestions of which services to cut, medical profes-
sionals ultimately have to make these difficult
decisions.
A further complicating factor, well illustrated by
Herceptin but seen in many other cases, is the suscepti-
bility of these decisions to external pressures.15 16 The
relative media and public appeal of “sexy” versus “Cin-
derella” services and the power of different clinical
specialties have always exerted external pressure on
allocation of resources in the NHS (and other
healthcare systems).17 In the case of Herceptin, high
profile patients, media bias, industry support, and
political gaming put considerable pressure on the NHS
to offer this drug in early stage breast cancer. NICE’s
decision highlights the “rubber stamping” role that this
government appointed body seems to have adopted,
and that in priority setting NICE’s bark is much worse
than its bite.18
Their decision is understandable as an appeal to
the emotional principle of “rule of rescue” (the
imperative people feel to rescue identified individuals
facing avoidable death).19 When new technologies
(such as Herceptin) arise, it is relatively easy to pit the
known patient in need against either the system in
general or a set of “anonymous” patients elsewhere.
Priority setting tends to be focused at this “anony-
mous” level.20 But no patient is anonymous, especially
not to the attending doctor who also has the ultimate
rationing responsibility in the current system. We have
deliberately not discussed priority setting between
Herceptin and, for example, neonatal intensive care or
hip replacements.We think that it is important to focus,
for a change, on the “clinical coal face” as this is the
ultimate reality. We, not NICE, have to choose which
other treatments will not be provided and which of our
patients will not be treated.
Nobody has suggested what treatments we cut in
favour of Herceptin—not the media, medical advocates
of the drug, the courts who upheld patient appeals, or
NICE. It would be especially interesting to know what
the secretary of state for health would like us to cut.
Political pressure, patient advocacy, and media
hyperbole should not determine who is treated and
what they are treated with. NICE is an established sys-
tem, but it currently creates more problems than solu-
tions. This organisation must be given responsibility to
decide what should be cut to fund newly recom-
mended technologies or the ability to allocate extra
funds for implementation (or both). Without these
Table 1 Cost and potential benefits of adjuvant cancer treatments in Norfolk and Norwich University Hospital Trust
Treatment
No of patients
given treatment
Drug cost
(£000) Proven benefit
Potential benefit at our
hospital
Cost per patient
cured (£000)
Adjuvant chemotherapy for lung
cancer
15 23 5-15% improved 5 year overall
survivalw3
1 extra patient cured 23
Oxaliplatin as adjuvant therapy for
colon cancer compared with
fluorouracil alone
20 137 5% improved 3 year disease-free
survival; no benefit to overall
survivalw4
1 extra patient without
recurrence at 3 years
137
Neoadjuvant chemotherapy for
oesophageal cancer
25 8 9% improved 5 year survivalw5 3 extra patients cured 2.67
Rituximab in addition to CHOP for
non-Hodgkin lymphoma in patients
over 60
25 215 13% improved 2 year overall
survivalw6
3 extra patients cured 71.67
Adjuvant aromatase inhibitors in
postmenopausal breast cancer
270 120 3.7% improved disease-free survival
compared with tamoxifen; no benefit
to overall survivalw7
8 extra patients without
recurrence at 5 years
15
Total 355 503 16 extra patients cured
Herceptin for early stage breast
cancer
75 1940 0-4% improved 4 year overall
survivalw1 w2
3 extra patients cured 650
CHOP=cyclophosphamide, doxorubicin, vincristine, and prednisolone.
Table 2 Cost and potential benefits of palliative cancer treatments in Norfolk and Norwich University Hospital Trust
Treatment
No of patients
given treatment
Drug cost
(£000) Proved benefit
Cost per quality adjusted life year
gained (£000)
Second line docetaxel for lung cancer 15 45 Median survival improved by 2 months 17.55w8
Taxanes for breast cancer 35 150 Median time to progression improved
by 5-16 weeks
19w9
Temozolomide for glioma 18 100 Median survival increased by 6 weeks 35w10
Paclitaxel for ovarian cancer 50 100 Median survival improved by 0-14
months
7-45w11
Irinotecan and oxaliplatin, first line
treatment for colorectal cancer
45 300 Median survival increased by 2-3
months
Irinotecan 30-58, oxaliplatin 23-57 per
progression-free life yearw12
Herceptin for breast cancer 15 250 Median time to progression improved
by 4 months
37.5 per quality adjusted life year in
combination regimen, 7.5 per life year as
single agentw13
Gemcitabine for pancreatic cancer 30 55 Median survival improved by 6 weeks 7-18w14
Total 208 997
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changes Herceptin will not be the last controversial
case of “rationing by media.”
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Somebody cut my brain in half with a Sabatier knife
“The moment I first realised that my world had changed was just
after I’d finished a busy surgery and I went out to have a
conversation with one of the receptionists and I started to feel
very odd. I felt as though somebody had taken a Sabatier knife
and cut my brain in half. I felt disconnected and unplugged and I
knew at that moment, that this was something major.” Dr Chris
Manning is a former general practitioner and also a patient—he
has had severe depression, and this is how he first realised that
something was wrong. You can listen to the rest of his story in
one of BMJ Learning’s most recent multimedia modules—on
anxiety and depression, which we have produced in association
with the National Institute for Health and Clinical Excellence
(NICE). The module offers an interactive guide to the NICE
guidelines and contains a short video outlining the patient’s
perspective on how best to put them into practice.
One of the challenges that providers of online learning face is
how to use multimedia in a way that is effective and economical
and that helps learning. According to Donald Clark, a leading
authority in multimedia learning in the UK, “early multimedia
learning looked like a car that had been cobbled together from
different scrap yards with components of different sizes, colours,
models and ages. It was a mongrel beast.”1 He was referring to the
early flood of learning websites that had loud music and equally
loud colour. Videos were mixed with animation, and graphics
popped up all over the screen. The designers loved it, but users
were at first bemused and then distracted, and in the end they
learnt little. BMJ Learning, however, has gone for short and
simple videos of patients and experts speaking to camera, but we
want to hear from you to find out if we have got it right. Would
you prefer doctors speaking in sherry ripe voiceovers à la Orson
Welles or slapstick or even costume romps? Let us know.
One of the main thrusts of the NICE guidelines on depression
is to recommend a stepped care approach—that is, to offer
treatment that is tailored to the severity of the patient’s symptoms.
For example, NICE recommends that “for patients with mild
depression who do not want an intervention or who, in the
opinion of the healthcare professional, may recover with no
intervention, a further assessment should be arranged, normally
within 2 weeks (watchful waiting).”2 For patients with mild
depression who do need an intervention, NICE advises guided
self help programmes based on the principles of cognitive
behaviour therapy in most circumstances.2 Chris Manning
describes his first experience of stepped care as a bear hug from
his Russian psychiatrist, who visited him at home. According to
Chris, he gave him “optimism and hope—evidence based
nutrients for the human mind.”
Kieran Walsh clinical editor, BMJ Learning
(bmjlearning@bmjgroup.com)
1 EPIC Group. White paper: Media rich is not always mind rich.
www.epic.co.uk/content/resources/white_papers/media_mix.htm.
2 National Institute for Health and Clinical Excellence. CG23 Depression: NICE
guideline. www.nice.org.uk/guidance/CG23/niceguidance/doc/English.
Summary points
Treating early breast cancer with trastuzumab
(Herceptin) would cost our hospital trust £1.9m
(€2.9m; $3.6m) per annum in drug costs alone
Guidance from the National Institute for Health
and Clinical Excellence on new treatments does
not have additional funding attached, and does
not recommend which services should be cut to
pay for new treatments
NICE should be given responsibility to decide
what should be cut to fund newly recommended
technologies or the ability to allocate extra funds
for implementation, or both
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